<DOC>
	<DOCNO>NCT01164891</DOCNO>
	<brief_summary>This open-label , non-randomized study assess mass balance , metabolism , rout rate elimination well efficacy safety RO5185426 ( RG7204 ; PLEXXIKON ; PLX4032 ) previously treat untreated patient metastatic melanoma . Patients receive continuous twice daily oral treatment RO5185426 . On Day 15 , 14C-labeled dose administer . Anticipated time study treatment disease progression occur .</brief_summary>
	<brief_title>A Pharmacokinetic Metabolism Study 14C-labeled RO5185426 Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm metastatic melanoma , surgically incurable unresectable Stage IIIc IV ( AJCC ) Prior treatment metastatic melanoma allow ; &gt; /= 28 day must elapse since previous systemic treatment prior first administration study drug Positive BRAF V600E mutation result ( Roche CoDx test ) ECOG performance status 01 Adequate hematologic , renal liver function Body Mass Index ( BMI ) 18 32 kg/m2 inclusive Active CNS lesion History know spinal cord compression , carcinomatous meningitis Anticipated ongoing administration anticancer therapy administer study Refractory nausea vomiting , medical condition capable alter absorption , metabolism elimination study drug Known clinically significant active infection Known HIV positivity AIDSrelated illness , active HBV , active HCV Previous malignancy within past 5 year , except basal squamous cell carcinoma skin , melanoma situ , carcinoma situ cervix Clinically significant cardiovascular disease incident within 6 month prior study drug administration Patients least one dose study drug ( RO5185426 comparator ) clinical trial include RO5185426</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>